Skip to main content
BOTANIX PHARMACEUTICALS LTD logo

BOTANIX PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · BOT ISIN · AU000000BOT2 ASX Manufacturing
Open in API
Filings indexed 1,209 across all filing types
Latest filing 2022-09-01 Capital/Financing Update
Country AU Australia
Listing ASX BOT

About BOTANIX PHARMACEUTICALS LTD

https://botanixpharma.com/

Botanix Pharmaceuticals Ltd is a clinical-stage pharmaceutical company focused on the development and commercialization of novel topical treatments for serious skin conditions. The company utilizes its proprietary Permetrex™ skin delivery technology, which is designed to improve the delivery of active ingredients through the skin. Its primary product, Sofdra™ (sofpironium bromide), is an FDA-approved prescription topical gel for the treatment of primary axillary hyperhidrosis. The company's research and development pipeline also includes clinical-stage candidates for the treatment of acne, rosacea, and atopic dermatitis. Botanix aims to address significant unmet medical needs in dermatology by providing innovative therapeutic solutions with enhanced safety and efficacy profiles.

Recent filings

Filing Released Lang Actions
Proposed issue of securities - BOT 5 pages 28.0KB
Capital/Financing Update Classification · 100% confidence The document is an announcement from Botanix Pharmaceuticals Ltd regarding a proposed issue of securities, specifically a placement of 7,575,758 ordinary fully paid shares. It includes details such as the issue price, proposed issue date, conditions including shareholder approval, fees to brokers, and the purpose of the capital raise. The document is structured as an official announcement to the ASX (Australian Securities Exchange) about a capital raising event. It does not contain financial statements or detailed financial performance data, nor is it a report or transcript. It is clearly an update on financing activity, specifically a new share issue. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (6231 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2022-09-01 English
Proposed issue of securities - BOT 5 pages 28.2KB
Capital/Financing Update Classification · 95% confidence The document is an announcement from Botanix Pharmaceuticals Ltd regarding a proposed issue of securities, specifically a placement of unlisted options. It details the number of securities, issue price, proposed issue date, and compliance with ASX listing rules. The content is focused on informing the market about a capital raising activity rather than presenting financial results or detailed reports. There are no financial statements or management discussions present. The document fits the category of updates on company fundraising or capital structure changes, which corresponds to Capital/Financing Update (CAP). The document length and detail confirm it is not a brief notice or a regulatory filing but a substantive announcement about a capital issue.
2022-09-01 English
Proposed issue of securities - BOT 5 pages 28.3KB
Capital/Financing Update Classification · 95% confidence The document is an announcement from Botanix Pharmaceuticals Ltd regarding a proposed issue of securities, specifically unlisted options. It details the number of securities, issue price, proposed issue date, and compliance with ASX listing rules. The content focuses on the company's capital raising activity through a placement or other type of issue. There are no financial statements, management discussion, or detailed financial results included. The document is a formal announcement of a capital raising event rather than a full financial report or other regulatory filing. Therefore, it fits the category of Capital/Financing Update (CAP). The document length (7038 characters) supports it being a detailed announcement rather than a brief notice or a full report.
2022-09-01 English
Proposed issue of securities - BOT 5 pages 28.3KB
Capital/Financing Update Classification · 100% confidence The document is an announcement from Botanix Pharmaceuticals Ltd regarding a proposed issue of securities, specifically unlisted options. It details the number of securities, issue price, proposed issue date, and compliance with ASX listing rules. The content focuses on the planned placement or issue of new securities rather than financial results, management changes, or other report types. The document is about capital raising activities and changes in the company's capital structure. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a brief notice or a report publication announcement but a substantive announcement about financing.
2022-09-01 English
Preliminary Final Report 11 pages 338.1KB
Annual Report Classification · 95% confidence The document is titled 'Appendix 4E Preliminary Final report' for the financial year ended 30 June 2022, which is a regulatory filing format used in Australia for preliminary final reports. It contains detailed financial statements including consolidated statement of profit or loss and other comprehensive income, and consolidated statement of financial position. It also includes a review of operations and results, discussion of clinical development pipeline, and other management commentary. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The content includes comprehensive financial data and operational review for the full fiscal year, consistent with an annual report. The document references the Annual Report lodged with this report, but this document itself contains substantive financial data and analysis. Therefore, this document is best classified as an Annual Report (10-K equivalent).
2022-08-30 English
Trading Halt 2 pages 176.7KB
Capital/Financing Update Classification · 95% confidence The document is a market announcement from Botanix Pharmaceuticals Ltd regarding a trading halt requested pending a forthcoming announcement related to a potential capital raising. It references ASX Listing Rule 17.1 and does not contain any financial data, report content, or detailed disclosures. The document is short (2135 characters) and serves as a notification of a trading halt rather than a financial report or detailed update. This fits the category of Capital/Financing Update (CAP) because it concerns a capital raising event and trading halt related to it.
2022-08-30 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.